{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:37:40Z","timestamp":1784039860078,"version":"3.55.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1317,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1111\/j.1365-2133.2011.10698.x","type":"journal-article","created":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T08:02:41Z","timestamp":1319184161000},"page":"298-305","source":"Crossref","is-referenced-by-count":120,"title":["Adalimumab (antitumour necrosis factor-\u03b1) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study"],"prefix":"10.1093","volume":"166","author":[{"given":"H.H.","family":"van der Zee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Laman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.A.","family":"Dik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Prens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,1,23]]},"reference":[{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0190-9622(96)90321-7","article-title":"The prevalence of hidradenitis suppurativa and its potential precursor lesions","volume":"35","author":"Jemec","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","article-title":"Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies","volume":"59","author":"Revuz","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2230.1996.tb00145.x","article-title":"Hidradenitis suppurativa - characteristics and consequences","volume":"21","author":"Jemec","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2133.2009.09430.x","article-title":"Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study.","volume":"162","author":"van der Zee","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2133.2007.08332.x","article-title":"Long-term efficacy of a single course of infliximab in hidradenitis suppurativa","volume":"158","author":"Mekkes","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","article-title":"A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa","volume":"60","author":"Lee","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","article-title":"An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa","volume":"158","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/QCO.0b013e3283428d07","article-title":"Hidradenitis suppurativa: a review of cause and treatment","volume":"24","author":"Yazdanyar","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14728222.12.9.1085","article-title":"Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis","volume":"12","author":"Fantuzzi","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB17|cit17","first-page":"729","volume-title":"Dermatologic Surgery: Principles and Practice","author":"Hurley","year":"1989"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s004030100219","article-title":"A modified ex vivo skin organ culture system for functional studies","volume":"293","author":"Companjen","year":"2001","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J Immunol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB20|cit20","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-3083.2011.04123.x","article-title":"Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa","author":"Gulliver","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2011.10698.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jdermsci.2007.06.006","article-title":"Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation","volume":"48","author":"Marble","year":"2007","journal-title":"J Dermatol Sci"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2011.10698.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2011.10698.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T08:53:58Z","timestamp":1676364838000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/166\/2\/298\/6613636"}},"subtitle":["Adalimumab ameliorates inflammation in HS"],"short-title":[],"issued":{"date-parts":[[2012,1,23]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10698.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.724197184.793501398","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1,23]]}}}